Hye Jin Baek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hye Jin Baek has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Dong-Hyun Kim
Department of Social and Preventive Medicine, Hallym University College of Medicine, Chuncheon, Republic of Korea
4 shared publications - Jina Han
Department of Preventive Medicine and Public Health, Ajou University School of Medicine, Suwon, Korea
4 shared publications - June-Woo Lee
Division of Clinical Research for Vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Cheongju, Korea
4 shared publications - Jung Ae Kim
College of Nursing, Kyungbok University, Pocheon-si, Gyeonggi-do, Republic of Korea
4 shared publications - Ah-Ra Kim
Division of Clinical Research for Vaccine, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Cheongju, Korea
3 shared publications - Eunbi Noh
National Radiation Emergency Medical Center, Korea Institute of Radiological and Medical Sciences, Seoul, Korea
3 shared publications
Latest Publications
- Open Access
Employment type and non-compliance with SARS-CoV-2 diagnostic testing: insights from a nationwide seroprevalence study in South Korea
Objectives: To assess variations in compliance with SARS-CoV-2 diagnostic testing by examining the prevalence of unreported infections according to socioeconomic factors including occupation and employment type. We hypothesised that individuals in more precarious employment conditions would be less likely to undergo COVID-19 testing. Design: Nationwide follow-up survey linked to a prior seroprevalence study (K-SEROSMART). Setting: General population-based study conducted across 258 counties in South Korea. Participants: The final analysis included 4502 individuals aged 19 years and older who completed both the socioeconomic survey and SARS-CoV-2 antibody testing and were reactive for anti-nucleocapsid (N) antibodies. Primary outcome measures: The primary outcome was non-compliance with COVID-19 diagnostic testing, defined as the absence of a self-reported confirmed diagnosis among individuals who tested reactive for anti-SARS-CoV-2 nucleocapsid (N) antibodies, indicating a history of natural infection. Results: Non-compliance with diagnostic testing was significantly associated with socioeconomic characteristics. Self-employed individuals (adjusted OR (aOR) 1.97, 95% CI 1.47 to 2.65) and non-regular workers (aOR 1.45, 95% CI 1.09 to 1.93) had higher odds of unreported infection compared with regular workers. In the analysis by occupational group, certain occupations showed significant associations in the univariate analysis; however, these associations did not retain statistical significance in the multivariable analysis. Conclusions: Socioeconomic disparities play an important role in compliance with COVID-19 diagnostic testing. Individuals in precarious employment may face barriers to testing, contributing to undetected infections. Policies that improve access to testing and reduce employment-related constraints, such as paid sick leave, may help mitigate these disparities. Future research should investigate the specific reasons underlying non-compliance with testing and assess its contribution to community transmission.
Open AccessEmployment type and non-compliance with SARS-CoV-2 diagnostic testing: insights from a nationwide seroprevalence study in South Korea
Objectives: To assess variations in compliance with SARS-CoV-2 diagnostic testing by examining the prevalence of unreported infections according to socioeconomic factors including occupation and employment type. We hypothesised that individuals in more precarious employment conditions would be less likely to undergo COVID-19 testing. Design: Nationwide follow-up survey linked to a prior seroprevalence study (K-SEROSMART). Setting: General population-based study conducted across 258 counties in South Korea. Participants: The final analysis included 4502 individuals aged 19 years and older who completed both the socioeconomic survey and SARS-CoV-2 antibody testing and were reactive for anti-nucleocapsid (N) antibodies. Primary outcome measures: The primary outcome was non-compliance with COVID-19 diagnostic testing, defined as the absence of a self-reported confirmed diagnosis among individuals who tested reactive for anti-SARS-CoV-2 nucleocapsid (N) antibodies, indicating a history of natural infection. Results: Non-compliance with diagnostic testing was significantly associated with socioeconomic characteristics. Self-employed individuals (adjusted OR (aOR) 1.97, 95% CI 1.47 to 2.65) and non-regular workers (aOR 1.45, 95% CI 1.09 to 1.93) had higher odds of unreported infection compared with regular workers. In the analysis by occupational group, certain occupations showed significant associations in the univariate analysis; however, these associations did not retain statistical significance in the multivariable analysis. Conclusions: Socioeconomic disparities play an important role in compliance with COVID-19 diagnostic testing. Individuals in precarious employment may face barriers to testing, contributing to undetected infections. Policies that improve access to testing and reduce employment-related constraints, such as paid sick leave, may help mitigate these disparities. Future research should investigate the specific reasons underlying non-compliance with testing and assess its contribution to community transmission.
- Open Access
- 5 February 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Protective Effectiveness of Sars-Cov-2 Infection Risk Among Hybrid, Vaccine, and Infection-induced Immunity Against the Omicron Variant, K-Serosmart
Background: Estimating infection risk from SARS-CoV-2 Omicron and post-Omicron sub-variants is challenging due to the high number of unconfirmed infections. We compared breakthrough infection risks among individuals with hybrid, vaccine-only, and infection-only immunity in South Korea, incorporating laboratory-confirmed and serology-inferred infections. Methods: Using nationwide surveillance data (August–December 2022), immunity was classified by vaccination history and spike (S) and nucleocapsid (N) antibody profiles. Outcomes were assessed using two definitions: conservative (laboratory-confirmed cases) and inclusive (serology-inferred infections identified by changes in N-antibody titers). Infection dates for unconfirmed events were imputed via predictive mean matching, enabling Kaplan–Meier analyses. Time-varying Cox models estimated log hazard ratios (log-HRs). Results: Including serology markedly increased four-month cumulative infection risk estimates: hybrid immunity rose from 2% to 20%, infection-only from 4% to 24%, and vaccine-only from 30% to 40%. With these additional infections, the relative advantage of hybrid immunity narrowed. Under the conservative definition, log-HRs declined for vaccine-only vs hybrid (4.10–2.34) and infection-only vs hybrid (1.56–0.31). Under the inclusive definition, the vaccine-only log-HR fell from 3.44 to 0.13, and the infection-only log-HR shifted from 3.31 to −0.56, indicating greater protection for infection-only immunity by month four. Conclusions: Because confirmed cases largely capture symptomatic disease, vaccination appears to provide added protection against severe outcomes, though this benefit wanes within months. The rapid decline of hybrid immunity and the large burden of unconfirmed infections highlight the need for routine serological surveillance to detect silent transmission and timely booster campaigns to mitigate severe disease during Omicron-driven waves.
- 5 February 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Open AccessProtective Effectiveness of Sars-Cov-2 Infection Risk Among Hybrid, Vaccine, and Infection-induced Immunity Against the Omicron Variant, K-Serosmart
Background: Estimating infection risk from SARS-CoV-2 Omicron and post-Omicron sub-variants is challenging due to the high number of unconfirmed infections. We compared breakthrough infection risks among individuals with hybrid, vaccine-only, and infection-only immunity in South Korea, incorporating laboratory-confirmed and serology-inferred infections. Methods: Using nationwide surveillance data (August–December 2022), immunity was classified by vaccination history and spike (S) and nucleocapsid (N) antibody profiles. Outcomes were assessed using two definitions: conservative (laboratory-confirmed cases) and inclusive (serology-inferred infections identified by changes in N-antibody titers). Infection dates for unconfirmed events were imputed via predictive mean matching, enabling Kaplan–Meier analyses. Time-varying Cox models estimated log hazard ratios (log-HRs). Results: Including serology markedly increased four-month cumulative infection risk estimates: hybrid immunity rose from 2% to 20%, infection-only from 4% to 24%, and vaccine-only from 30% to 40%. With these additional infections, the relative advantage of hybrid immunity narrowed. Under the conservative definition, log-HRs declined for vaccine-only vs hybrid (4.10–2.34) and infection-only vs hybrid (1.56–0.31). Under the inclusive definition, the vaccine-only log-HR fell from 3.44 to 0.13, and the infection-only log-HR shifted from 3.31 to −0.56, indicating greater protection for infection-only immunity by month four. Conclusions: Because confirmed cases largely capture symptomatic disease, vaccination appears to provide added protection against severe outcomes, though this benefit wanes within months. The rapid decline of hybrid immunity and the large burden of unconfirmed infections highlight the need for routine serological surveillance to detect silent transmission and timely booster campaigns to mitigate severe disease during Omicron-driven waves.
- Open Access
- 28 October 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-11
Effect of anti-S antibody titers on newly confirmed cases of COVID-19 in Korea: a community-based cohort study (K-SEROSMART Wave 2)
Coronavirus disease 2019 (COVID-19) continues to impact populations globally, raising concerns about immunity levels and risks to high-risk groups despite the lifting of the global health emergency in May 2023. While studies have tracked seroprevalence, few have comprehensively assessed long-term antibody persistence and COVID-19 risk, particularly regarding immunity changes due to vaccination and infection. This study aimed to estimate the population prevalence of SARS-CoV-2-specific antibodies, including anti-spike (anti-S) and anti-nucleocapsid (anti-N) antibodies, and to assess the risk of newly confirmed COVID-19 infections in Korea in December 2022. We conducted a follow-up survey and blood testing of 9,945 participants in the Korea Seroprevalence Study of Monitoring of SARS-CoV-2 Antibody Retention and Transmission (K-SEROSMART) Wave 1. The K-SEROSMART Wave 2 study employed a staged approach through public health centers nationwide, using mobile web, telephone, and face-to-face surveys. The follow-up survey (Wave 2) was conducted between December 6 and 27, 2022, four months after the initial survey (Wave 1) conducted in August 2022. Participants self-reported sociodemographic characteristics and health status and provided blood samples for the analysis of anti-spike (anti-S) and anti-nucleocapsid (anti-N) antibodies via electrochemiluminescence immunoassay. Population prevalence estimates were weighted for demographic data. Multivariate Cox proportional hazards regression was used to assess the relationship between anti-S antibody titers from Wave 1 and new COVID-19 cases, adjusting for age and sex. A total of 7,528 individuals participated, yielding a follow-up rate of 74.9%. The population-adjusted prevalence rates of anti-S and anti-N antibodies were 98.5% and 70.0%, respectively. The percentage of newly confirmed COVID-19 cases was significantly higher in individuals with anti-S antibody titers below 2,000 U/mL, 2,000–3,999 U/mL, 4,000–5,999 U/mL, 6,000–7,999 U/mL, and 8,000–9,999 U/mL than in those with titers above 18,000 U/mL (hazard ratio [HR] = 9.9, 95% confidence interval [CI] = 7.2–13.5; HR = 8.1, 95% CI = 5.8–11.3; HR = 7.1, 95% CI = 5.0–10.1; HR = 4.2, 95% CI = 2.8–6.3; HR = 2.0, 95% CI = 1.2–3.3, respectively). This study demonstrated the feasibility of conducting a seroepidemiological cohort survey on COVID-19 using a nationally representative sample. Additionally, this study quantified anti-S antibody titer levels that are associated with reduced risk of new infections within a community.
- 28 October 2025
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 25 (1) , 1-11
Open AccessEffect of anti-S antibody titers on newly confirmed cases of COVID-19 in Korea: a community-based cohort study (K-SEROSMART Wave 2)
Coronavirus disease 2019 (COVID-19) continues to impact populations globally, raising concerns about immunity levels and risks to high-risk groups despite the lifting of the global health emergency in May 2023. While studies have tracked seroprevalence, few have comprehensively assessed long-term antibody persistence and COVID-19 risk, particularly regarding immunity changes due to vaccination and infection. This study aimed to estimate the population prevalence of SARS-CoV-2-specific antibodies, including anti-spike (anti-S) and anti-nucleocapsid (anti-N) antibodies, and to assess the risk of newly confirmed COVID-19 infections in Korea in December 2022. We conducted a follow-up survey and blood testing of 9,945 participants in the Korea Seroprevalence Study of Monitoring of SARS-CoV-2 Antibody Retention and Transmission (K-SEROSMART) Wave 1. The K-SEROSMART Wave 2 study employed a staged approach through public health centers nationwide, using mobile web, telephone, and face-to-face surveys. The follow-up survey (Wave 2) was conducted between December 6 and 27, 2022, four months after the initial survey (Wave 1) conducted in August 2022. Participants self-reported sociodemographic characteristics and health status and provided blood samples for the analysis of anti-spike (anti-S) and anti-nucleocapsid (anti-N) antibodies via electrochemiluminescence immunoassay. Population prevalence estimates were weighted for demographic data. Multivariate Cox proportional hazards regression was used to assess the relationship between anti-S antibody titers from Wave 1 and new COVID-19 cases, adjusting for age and sex. A total of 7,528 individuals participated, yielding a follow-up rate of 74.9%. The population-adjusted prevalence rates of anti-S and anti-N antibodies were 98.5% and 70.0%, respectively. The percentage of newly confirmed COVID-19 cases was significantly higher in individuals with anti-S antibody titers below 2,000 U/mL, 2,000–3,999 U/mL, 4,000–5,999 U/mL, 6,000–7,999 U/mL, and 8,000–9,999 U/mL than in those with titers above 18,000 U/mL (hazard ratio [HR] = 9.9, 95% confidence interval [CI] = 7.2–13.5; HR = 8.1, 95% CI = 5.8–11.3; HR = 7.1, 95% CI = 5.0–10.1; HR = 4.2, 95% CI = 2.8–6.3; HR = 2.0, 95% CI = 1.2–3.3, respectively). This study demonstrated the feasibility of conducting a seroepidemiological cohort survey on COVID-19 using a nationally representative sample. Additionally, this study quantified anti-S antibody titer levels that are associated with reduced risk of new infections within a community.
- Open Access
- 17 August 2023
- Published by Korean Society of Epidemiology in Epidemiology and Health
- Vol. 45, e2023075
Korea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-SEROSMART): findings from national representative sample
OBJECTIVES: We estimated the population prevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including unreported infections, through a Korea Seroprevalence Study of Monitoring of SARS-CoV-2 Antibody Retention and Transmission (K-SEROSMART) in 258 communities throughout Korea.METHODS: In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling. During face-to-face household interviews, participants self-reported their health status, COVID-19 diagnosis and vaccination history, and general characteristics. Subsequently, participants visited a community health center or medical clinic for blood sampling. Blood samples were analyzed for the presence of antibodies to spike proteins (anti-S) and antibodies to nucleocapsid proteins (anti-N) SARS-CoV-2 proteins using an electrochemiluminescence immunoassay. To estimate the population prevalence, the PROC SURVEYMEANS statistical procedure was employed, with weighting to reflect demographic data from July 2022.RESULTS: In total, 9,945 individuals from 5,041 households were surveyed across 258 communities, representing all basic local governments in Korea. The overall population-adjusted prevalence rates of anti-S and anti-N were 97.6% and 57.1%, respectively. Since the Korea Disease Control and Prevention Agency has reported a cumulative incidence of confirmed cases of 37.8% through July 31, 2022, the proportion of unreported infections among all COVID-19 infection was suggested to be 33.9%.CONCLUSIONS: The K-SEROSMART represents the first nationwide, community-based seroepidemiologic survey of COVID-19, confirming that most individuals possess antibodies to SARS-CoV-2 and that a significant number of unreported cases existed. Furthermore, this study lays the foundation for a surveillance system to continuously monitor transmission at the community level and the response to COVID-19.
- 17 August 2023
- Published by Korean Society of Epidemiology in Epidemiology and Health
- Vol. 45, e2023075
Open AccessKorea Seroprevalence Study of Monitoring of SARS-COV-2 Antibody Retention and Transmission (K-SEROSMART): findings from national representative sample
OBJECTIVES: We estimated the population prevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including unreported infections, through a Korea Seroprevalence Study of Monitoring of SARS-CoV-2 Antibody Retention and Transmission (K-SEROSMART) in 258 communities throughout Korea.METHODS: In August 2022, a survey was conducted among 10,000 household members aged 5 years and older, in households selected through two stage probability random sampling. During face-to-face household interviews, participants self-reported their health status, COVID-19 diagnosis and vaccination history, and general characteristics. Subsequently, participants visited a community health center or medical clinic for blood sampling. Blood samples were analyzed for the presence of antibodies to spike proteins (anti-S) and antibodies to nucleocapsid proteins (anti-N) SARS-CoV-2 proteins using an electrochemiluminescence immunoassay. To estimate the population prevalence, the PROC SURVEYMEANS statistical procedure was employed, with weighting to reflect demographic data from July 2022.RESULTS: In total, 9,945 individuals from 5,041 households were surveyed across 258 communities, representing all basic local governments in Korea. The overall population-adjusted prevalence rates of anti-S and anti-N were 97.6% and 57.1%, respectively. Since the Korea Disease Control and Prevention Agency has reported a cumulative incidence of confirmed cases of 37.8% through July 31, 2022, the proportion of unreported infections among all COVID-19 infection was suggested to be 33.9%.CONCLUSIONS: The K-SEROSMART represents the first nationwide, community-based seroepidemiologic survey of COVID-19, confirming that most individuals possess antibodies to SARS-CoV-2 and that a significant number of unreported cases existed. Furthermore, this study lays the foundation for a surveillance system to continuously monitor transmission at the community level and the response to COVID-19.